RBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Globus Medical (NYSE:GMED) and raises the price target from $76 to $78.
August 07, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on Globus Medical and raises the price target from $76 to $78.
The raised price target and maintained Outperform rating from RBC Capital are positive signals for investors, likely leading to a short-term increase in GMED's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100